A Chat with Dr. Xiling Shen: Professor and the Chief Scientific officer of the Terasaki Institute for Biomedical Innovation; Entrepreneur; founder and Chief Executive Officer of Xilis Inc.; previously director of Woo Center for Big Data and Precision Health at Duke University, steering committee chair of the NCI Patient-Derived Model of Cancer Consortium, chair of the NCI Patient-Derived Model of Cancer Consortium, co-chair of the NCI Tissue Engineering Consortium, and cancer track chair of Biomedical Engineering Society 2019; Dr. Shen's lab specializes in precision medicine and systems biology. His members integrate biological engineering , and computational techniques to study cancer, stem cells, and gut-brain axis.

This week, Stephen Ibaraki has an exclusive interview with Dr. Xiling Shen.

Dr. Shen is currently a professor and the chief scientific officer of the Terasaki Institute for Biomedical Innovation and the founder and chief executive officer of Xilis Inc, which raised an $89M Series A to advance precision medicine.

He was formerly the Hawkins Family Associate Professor in the Department of Biomedical Engineering and the director of the Woo Center for Big Data and Precision Health at Duke University.

He received his BS, MS, and PhD degrees from Stanford University and the NSF career award at Cornell University. He was the steering committee chair of the NCI Patient-Derived Model of Cancer Consortium, co-chair of the NCI Tissue Engineering Consortium, and cancer track chair of Biomedical Engineering Society 2019. His lab studies precision medicine from a systems biology perspective. Areas of interests include cancer, stem cells, the gut-brain axis, and microbiome.